All lobbying filings

ALNYLAM PHARMACEUTICALS, INC.

ALNYLAM PHARMACEUTICALS, INC. filed a Q4 report for ALNYLAM PHARMACEUTICALS, INC. on January 20, 2026.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

All filings by ALNYLAM PHARMACEUTICALS, INC. · Everything ALNYLAM PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$390,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 1

CURTIS RHYNE

Previously held: Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing.

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Bills named in this filing 1

H.R. 4993
Joe Fiandra Access to Home Infusion Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.